Stay updated on Cabozantinib in Refractory Metastatic Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in Refractory Metastatic Colorectal Cancer Clinical Trial page.

Latest updates to the Cabozantinib in Refractory Metastatic Colorectal Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page now displays a 403 Forbidden screen with site chrome, replacing the previous study details. This indicates the page is currently inaccessible due to permissions or server restrictions rather than a content update.SummaryDifference19%

- Check40 days agoChange DetectedThe page's revision tag changed from v3.6.5 to v3.6.6, indicating a new page revision. The visible study details appear unchanged by this metadata update.SummaryDifference0.1%

- Check62 days agoChange DetectedThe page revision updated from v3.6.4 to v3.6.5, signaling a backend update rather than a modification to the study details.SummaryDifference0.0%

- Check77 days agoChange DetectedRevision changed from v3.6.3 to v3.6.4 on the study page, indicating a patch-level update to the page framework. There is no indication that study content such as enrollment, results, or eligibility criteria has been altered.SummaryDifference0.0%

- Check98 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, signaling a new release of the site content or backend. This change does not modify the study data or visible content.SummaryDifference0.0%

- Check105 days agoChange DetectedThe page revision label changed from v3.6.0 to v3.6.2 in the site metadata. This reflects a software update to the page, without altering the study details.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib in Refractory Metastatic Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in Refractory Metastatic Colorectal Cancer Clinical Trial page.